Focus on Diabetes Care

Back to articles

Glimepiride Provides Surprising Improvements in Insulin Resistance


In older patients with type 2 diabetes, glimepiride (Amaryl—Aventis) appears to exert significant hypoglycemic effects through reductions in insulin resistance, according to a study from Japan. Rather than increasing endogenous insulin production as most sulfonylureas do, glimepiride plus acarbose (Precose—Bayer) in this study appeared to increase signficantly plasma levels of a cytokine, adiponectin, and to thereby reduce plasma levels of tumor necrosis factor- α (TNF-α, a known inducer of insulin resistance).


Tsunekawa T et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care. 2003;26:285–9.